Tumor-naïve multimodal profiling of circulating tumor DNA to detect minimal residual disease in solid tumors
Key finding:
The tumor-naïve method could be a reliable alternative to monitor ctDNA when obtaining high-quality tissue samples is challenging. The performance of this method was better in high ctDNA-shedding cancer or at the metastatic stage.Authors:
Tu Nguyen, Van-Anh Nguyen Hoang, Trong Hieu Nguyen, Trung Hieu Tran, Ngoc Nguyen, Tho Thi Le Vo, Duy Sinh Nguyen, Hoa Giang, Hoai-Nghia Nguyen, and Lan N. TuPublisher:Therapeutic Advances in Medical Oncology
Publication date:18 November 2025This publication supports for the following genetic testing:
Tumor Genomic and Transcriptomic Analysis Integrated With Liquid Biopsy ctDNA Monitoring: Analytical Validation and Clinical Insights
Key finding:
Comprehensive genomic profiling (CGP) is a time- and tissue- efficient method to help guide precision oncology. To enhance the clinical utility of CGP, we investigated the performance of a novel strategy integrating tumor DNA and mRNA profiling, together with liquid biopsy ctDNA monitoring. Comprehensive genomic and transcriptomic profiling could reliably unveil genetic details not provided by DNA-only CGP. The integration of ctDNA detection further helped detect tumor-agnostic mutations and monitor treatment response.Authors:
Nam H. B. Tran, Thien-Phuc Hoang Nguyen, Vinh Quang Bui, Vu Thuong Le, Trong Khoa Mai, Van-Anh Nguyen Hoang, Tien Anh Nguyen, Minh-Duc Nguyen, Ha-Hieu Pham, Tho Thi Le Vo, My T. T. Ngo, Du Quyen Nguyen, Duy Sinh Nguyen, Hoai-Nghia Nguyen, Minh-Duy Phan, Hoa Giang, Lan N. TuPublisher:Cancer Medicine
Publication date:08 December 2025This publication supports for the following genetic testing:
Combination of BRCA deep targeted sequencing and shallow whole genome sequencing to detect homologous recombination deficiency in ovarian cancer
Key finding:
We developed an assay to accurately determine the homologous recombination deficiency status of ovarian tissue samples, including those with low DNA quality. This study was the first to analyze the prevalence and spectrum of homologous recombination deficiency in Vietnamese patients with ovarian cancer. Comprehensive assessment of homologous recombination deficiency should be performed instead of BRCA1/2 testing alone so that no patients miss their opportunity for PARPi treatment.Authors:
Thien-Phuc Nguyen Hoang , Nam H. B. Tran , Tien Anh Nguyen, My T. T. Ngo, Anh Duong Doan, Du Quyen Nguyen, Hung Sang Tang, Duy Sinh Nguyen, Cam Tu Nguyen Thi, Thanh Thuy Do Thi , Hoai-Nghia Nguyen, Hoa Giang and Lan N. TuPublisher:Frontier
Publication date:01 September 2025This publication supports for the following genetic testing:
Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer
Key finding:
The clinical utilization of circulating tumor DNA (ctDNA) in breast cancer (BC) management is not well-defined. In this prospective study, 168 patients with early-stage BC were recruited, serial blood samples were collected before and after surgery. Tumor-informed ctDNA testing was performed, which sequenced tumors for 95 genes followed by bespoke mPCR to track 1–9 mutations in the plasma. ctDNA was detected before surgery in 14.6%, 40.0%, 83.8%, and 80.0% of HR+ low-risk, HR+ high-risk, HR-HER2+ and HR-HER2- patients, respectively. Pre-operative ctDNA positivity was significantly associated with decreased disease-free survival (DFS) (adjusted HR = 3.09, 95% CI 2.65–80.0, p = 0.001). After a median 26.6-month follow-up, 11 patients relapsed, and ctDNA at landmark time point 2–4 weeks after surgery was detected in 50.0% (5/10) of cases. Landmark ctDNA clearance was associated with significantly longer DFS (p = 0.0009) and positive ctDNA persistence after adjuvant therapy occurred in 36.4% (4/11) of stage-III patients. During surveillance, ctDNA detection had 90.9% sensitivity and 98.8% specificity to predict recurrence, and median lead time of 9.7 months. Patients with detected ctDNA had shorter DFS than those with undetectable ctDNA (adjusted HR = 207.05, 95% CI 41.38- > 1000, p = 0.001). Therefore, ctDNA status both before and after surgery could help stratify recurrence risk for BC patients.Authors:
Sao Trung Nguyen, Van-Anh Nguyen Hoang, Vu Nguyen Trieu, Thanh Huyen Pham, Thi Cuc Dinh, Dinh Hoang Pham, Ngoc Nguyen, Dao Nguyen Vinh, Thanh Thuy Thi Do, Duy Sinh Nguyen, Hoai-Nghia Nguyen, Hoa Giang & Lan N. TuPublisher:npj Breast Cancer
Publication date:20 June 2025This publication supports for the following genetic testing:
Real-World Utilization and Performance of Circulating Tumor DNA Monitoring to Predict Recurrence in Solid Tumors
Key finding:
In the early-stage I-III, preoperative ctDNA detection rates were 66.7%, 84.6%, 54.3%, 52.6%, 93.3%, and 75.0% for lung, colorectal, breast, gastric, liver, and ovarian cancers, respectively. After surgery, 84.4% (38/45) of patients with recurrence had ctDNA detected in the plasma, while 96.3% (210/218) of patients with no recurrence had negative results. Postoperative ctDNA positivity significantly increased the risk of recurrence (P 100 [95% CI, 26.9 to >100.0) cancers. In the metastatic stage IV, pretreatment ctDNA detection rates were 80.0%, 87.7%, 73.3%, 70.6%, 91.7%, and 81.8% for lung, colorectal, breast, gastric, liver, and ovarian cancers, respectively. Case studies were presented to demonstrate utilization of ctDNA at all cancer stages.Authors:
Van-Anh Nguyen Hoang, MSc; Ngoc Nguyen, BSc; Duc Nhan Le, MD, MSc; Van Son Nguyen, MD; Huong Giang Nguyen Thi, MD; Hong Thang Vu, MD, PhD; Huu Hao Ho, MD; Hong Minh Le, MD, PhD; Tien Dung Nguyen, MD; Huu Nhan Vo, MD, MSc; Thu Suong Le Thi, MD; Van Tuan Ha, MD; Hoang Duong Nguyen, MD; Minh Phuong Nguyen Thi, MD, PhD; Kim Phuong Tran Thi, MD, PhD; Tran Doanh Vi, MD, PhD; Minh Tu Hoang, MD, MSc; Hoang Giang Vu, BSc; Tu Nguyen, MSc; Van T. Phan, MSc; Nguyen Huu Tam Phuc, BSc; Duy Sinh Nguyen, MD, PhD; Hoai-Nghia Nguyen, PhD; and Lan N. Tu, PhDPublisher:JCO Oncology Advances
Publication date:07 March 2025This publication supports for the following genetic testing:
Clinical trial and real-world evidence of circulating tumor DNA monitoring to predict recurrence in patients with resected colorectal cancer
Key finding:
Circulating tumor DNA (ctDNA) is a novel biomarker for predicting recurrence in colorectal cancer (CRC). Analysis from both clinical trials and real-world data indicates that ctDNA serves as an independent and strong prognostic biomarker for CRC recurrence. ctDNA testing may aid clinical decision-making by supporting personalized intervention and surveillance strategies.Authors:
H. T. Nguyen, V.-A. Nguyen Hoang, T. V. Nguyen , N. A. L. Trinh, T. H. Pham, D. N. Le, H. H. Ho, T. D. Nguyen, H. D. Nguyen, T. S. L. Thi, N. Nguyen, D. H. Tran, M. T. Le, T. C. Dinh, T. S. Nguyen, K. C. N. The, H. Mai, M. T. Chu, D. H. Pham, N. H. T. Phuc, D. N. Vinh, D.-N. Nguyen, X.-V. Nguyen, D. S. Nguyen, T. T. D. Thi, H. Giang, H.-N. Nguyen & L. N. TuPublisher:ESMO Real World Data and Digital Oncology
Publication date:24 September 2024This publication supports for the following genetic testing:
Analytical validation and clinical utilization of K-4CARE™: a comprehensive genomic profiling assay with personalized MRD detection
Key finding:
K-4CARE™ assay provides comprehensive and reliable genomic information that fulfills all guideline-based biomarker testing for both targeted therapy and immunotherapy. Integration of ctDNA tracking helps clinicians to further monitor treatment response and ultimately provide well-rounded care to cancer patients.Authors:
Thien-Phuc Nguyen Hoang, Tien Anh Nguyen, Nam H. B. Tran, Van-Anh Nguyen Hoang, Hong Thuy Thi Dao, Vu-Uyen Tran, Yen Nhi Nguyen, Anh Tuan Nguyen, Cam Tu Nguyen Thi, Thanh Thuy Do Thi, Duy Sinh Nguyen, Hoai-Nghia Nguyen, Hoa Giang, and Lan N. Tu.Publisher:Frontiers in Molecular Biosciences
Publication date:09 February 2024This publication supports for the following genetic testing:
Prevalence and genetic spectrum associated with hereditary colorectal cancer syndromes, the need to improve cancer risk awareness, and family cascade testing in Vietnam
Key finding:
Of all genetic test results, 3% (49/1632) were identified with mutations related to HCCS. Over 77% of them belonged to Lynch syndrome. PMS2 appeared to be the gene with the highest mutation frequency, while MLH1 was the lowest. This study provided new evidence for HCCS mutation spectrum in Vietnamese population and the success in promoting cascade test in high-risk family members through financial and technical support.Authors:
Huu-Thinh Nguyen, Y-Thanh Lu, Duc-Huy Tran, Ba-Linh Tieu, Kien-Trung Le, Truong-Vinh Ngoc Pham, Thanh-Thuy Thi Do, Dinh-Kiet Truong, Hoa Giang & Hung-Sang TangPublisher:Familial Cancer
Publication date:30 July 2023This publication supports for the following genetic testing:
Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients
Key finding:
Colorectal cancer (CRC) is the fifth most common cancer with rising prevalence in Vietnam. However, there is no data about the mutational landscape and actionable alterations in the Vietnamese patients.Authors:
Huu Thinh Nguyen, Trieu Vu Nguyen, Van-Anh Nguyen Hoang, Duc Huy Tran, Ngoc An Le Trinh, Minh Triet Le, Tuan-Anh Nguyen Tran, Thanh Huyen Pham, Thi Cuc Dinh, Tien Sy Nguyen, Ky Cuong Nguyen The, Hoa Mai, Minh Tuan Chu, Dinh Hoang Pham, Xuan Chi Nguyen, Thien My Ngo Ha, Duy Sinh Nguyen, Du Quyen Nguyen, Y-Thanh Lu, Thanh Thuy Do Thi, Dinh Kiet Truong, Quynh Tho Nguyen, Hoai-Nghia Nguyen, Hoa Giang, and Lan N. Tu.Publisher:Frontiers
Publication date:12 December 2022This publication supports for the following genetic testing:
Genetic landscape and personalized tracking of tumor mutations in Vietnamese women with breast cancer.
Key finding:
Using top-ranked mutations, we detected ctDNA in pre-operative plasma in 24.6–43.5% of the hormone-receptor-positive groups and 76.9–80.8% of the hormone-receptor-negative groups. The detection rate was associated with breast cancer subtypes and clinicopathological features that increased the risk of relapse. Interim analysis after a 15-month follow-up revealed post-operative detection of ctDNA in all three patients that had recurrence, with a lead time of 7–13 months ahead of clinical diagnosis.Authors:
Van-Anh Nguyen Hoang, Sao Trung Nguyen, Trieu Vu Nguyen, Thanh Huyen Pham, Phuoc Loc Doan, Ngoc Thanh Nguyen Thi, Minh Long Nguyen, Thi Cuc Dinh, Dinh Hoang Pham, Ngoc Mai Nguyen, Duy Sinh Nguyen, Du Quyen Nguyen, Y-Thanh Lu, Thanh Thuy Thi Do, Dinh Kiet Truong, Minh-Duy Phan, Hoai-Nghia Nguyen, Hoa Giang, Lan N. TuPublisher:Molecular Oncology
Publication date:10 December 2022This publication supports for the following genetic testing:
Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations
Key finding:
Targeted therapy with tyrosine kinase inhibitors (TKI) provides survival benefits to a majority of patients with non-small cell lung cancer (NSCLC). However, resistance to TKI almost always develops after treatment.Publisher:nature.com
Publication date:12 August 2021This publication supports for the following genetic testing:
Ultra-Deep Massive Parallel Sequencing of Plasma Cell-Free DNA Enables Large-Scale Profiling of Driver Mutations in Vietnamese Patients With Advanced Non-Small Cell Lung Cancer
Key finding:
Population-specific profiling of mutations in cancer genes is of critical importance for the understanding of cancer biology in general as well as the establishment of optimal diagnostics and treatment guidelines for that particular population.Publisher:Frontiers
Publication date:04 August 2020This publication supports for the following genetic testing:
1
2
